MX2017015572A - Derivados de 2-(1-heteroarilpiperazin-4-il)metil-1-4,-benzodioxano como antagonistas de alfa2c. - Google Patents

Derivados de 2-(1-heteroarilpiperazin-4-il)metil-1-4,-benzodioxano como antagonistas de alfa2c.

Info

Publication number
MX2017015572A
MX2017015572A MX2017015572A MX2017015572A MX2017015572A MX 2017015572 A MX2017015572 A MX 2017015572A MX 2017015572 A MX2017015572 A MX 2017015572A MX 2017015572 A MX2017015572 A MX 2017015572A MX 2017015572 A MX2017015572 A MX 2017015572A
Authority
MX
Mexico
Prior art keywords
heteroarylpiperazin
methyl
alpha2c
benzodioxane derivatives
alpha2c antagonists
Prior art date
Application number
MX2017015572A
Other languages
English (en)
Other versions
MX376027B (es
Inventor
Pohjakallio Antti
Pystynen Jarmo
Haikarainen Anssi
Wang Shouming
Kumpulainen Esa
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MX2017015572A publication Critical patent/MX2017015572A/es
Publication of MX376027B publication Critical patent/MX376027B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la fórmula I (fórmula I), en donde A es un anillo heterocíclico insaturado de cinco miembros sustituido opcionalmente que contiene 1, 2 ó 3 heteroátomos en el anillo de N, O o S que exhiben una actividad antagonista de alfa2C y de esta forma son útiles para el tratamiento de enfermedades o condiciones del sistema nervioso periférico o central.
MX2017015572A 2015-06-05 2016-06-03 Derivados de 2-(1-heteroarilpiperazin-4-il)metil-1-4,-benzodioxano como antagonistas de alfa2c. MX376027B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20150169 2015-06-05
PCT/FI2016/050400 WO2016193551A1 (en) 2015-06-05 2016-06-03 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2c antagonists

Publications (2)

Publication Number Publication Date
MX2017015572A true MX2017015572A (es) 2018-04-30
MX376027B MX376027B (es) 2025-03-07

Family

ID=56132965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015572A MX376027B (es) 2015-06-05 2016-06-03 Derivados de 2-(1-heteroarilpiperazin-4-il)metil-1-4,-benzodioxano como antagonistas de alfa2c.

Country Status (15)

Country Link
US (1) US10774074B2 (es)
EP (1) EP3303327B1 (es)
JP (1) JP6806711B2 (es)
KR (1) KR102653543B1 (es)
CN (1) CN107709316B (es)
AR (1) AR104882A1 (es)
AU (1) AU2016272220B2 (es)
CA (1) CA2985400C (es)
EA (1) EA033085B1 (es)
ES (1) ES2794584T3 (es)
IL (1) IL255352B (es)
MX (1) MX376027B (es)
TW (1) TWI704145B (es)
WO (1) WO2016193551A1 (es)
ZA (1) ZA201707466B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3029109A1 (en) * 2016-06-29 2018-01-04 Orion Corporation Benzodioxane derivatives and their pharmaceutical use
KR20240132345A (ko) 2022-01-07 2024-09-03 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 2,3-디히드로벤조[b][1,4]디옥신-2-일메틸)피페라진-1-일 유도체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788052A (fr) * 1971-08-26 1973-02-26 Science Union & Cie Societe Fr Nouveaux derives de la sydnone imine
US4590196A (en) * 1984-08-23 1986-05-20 Bristol-Myers Company Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003024942A1 (en) 2001-09-14 2003-03-27 Mitsubishi Pharma Corporation Thiazolidine derivative and medicinal use thereof
EA008537B1 (ru) 2002-04-03 2007-06-29 Орион Корпорейшн Полициклические соединения как эффективные антагонисты альфа2-адренорецептора
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
CA2517291C (en) 2003-03-19 2012-05-08 Exelixis, Inc. Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds

Also Published As

Publication number Publication date
JP2018520123A (ja) 2018-07-26
EP3303327A1 (en) 2018-04-11
ES2794584T3 (es) 2020-11-18
US20190292170A9 (en) 2019-09-26
US10774074B2 (en) 2020-09-15
KR102653543B1 (ko) 2024-04-03
CA2985400A1 (en) 2016-12-08
EA201792670A1 (ru) 2018-04-30
JP6806711B2 (ja) 2021-01-06
ZA201707466B (en) 2018-11-28
AR104882A1 (es) 2017-08-23
CA2985400C (en) 2023-08-29
TWI704145B (zh) 2020-09-11
WO2016193551A1 (en) 2016-12-08
NZ737533A (en) 2024-03-22
MX376027B (es) 2025-03-07
KR20180011316A (ko) 2018-01-31
EA033085B1 (ru) 2019-08-30
AU2016272220B2 (en) 2020-05-21
CN107709316B (zh) 2021-08-17
EP3303327B1 (en) 2020-03-11
TW201708208A (zh) 2017-03-01
CN107709316A (zh) 2018-02-16
IL255352A0 (en) 2017-12-31
US20180215739A1 (en) 2018-08-02
IL255352B (en) 2021-03-25
AU2016272220A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
MX373234B (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CL2016002011A1 (es) Derivados de heterociclos bicíclicos condensados sustituidos con 2-(het)arilo como agentes para combatir parásitos
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CL2016001911A1 (es) Compuesto heterocíclico fusionado
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
MX381911B (es) Derivados heterociclicos y uso de los mismos.
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
MX2018004664A (es) Antagonistas de ep4.
MX373268B (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas
MX395175B (es) Compuesto heterocíclico aromático nitrogenado, método de preparación para el mismo, composición farmacéutica del mismo, y aplicación del mismo.
MX2017015572A (es) Derivados de 2-(1-heteroarilpiperazin-4-il)metil-1-4,-benzodioxano como antagonistas de alfa2c.
MX2022010939A (es) Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao).
TR201905436T4 (tr) Terapötik bileşikler olarak yeni ep4 agonistleri.
CR20170261A (es) Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa
HUE040647T2 (hu) A központi idegrendszerrel kapcsolatos betegségek vagy állapotok kezelésére hasznos N-(hetero)aril-szubsztituált heterociklusos származékok
RU2014115406A (ru) Применение 8-(трифторметил)бензо[f][1,2,3,4,5]пентатиепин-6-амина в качестве антидепрессанта

Legal Events

Date Code Title Description
FG Grant or registration